Bioregenx (BRGX) Cash from Financing Activities (2022 - 2026)
Bioregenx (BRGX) recorded quarterly Cash from Financing Activities of -$50206.0 in Q1 2026, down 13.73% quarter-over-quarter from -$44143.0 in Q4 2025, and down 382.05% on a YoY basis from $17800.1 in Q1 2025.
Bioregenx (BRGX) Cash from Financing Activities (2022 - 2026) Analysis & Trends
Bioregenx's Cash from Financing Activities history runs 5 years deep, the most recent figure standing at -$50206.0 for Q1 2026.
- In Q1 2026, Cash from Financing Activities fell 382.05% year-over-year to -$50206.0; the TTM figure through Mar 2026 stood at -$6693.0 (down 104.49% YoY), while the FY2025 annual figure was $33098.0, down 92.51% from the prior year.
- Cash from Financing Activities was -$50206.0 for Q1 2026 at Bioregenx, down from -$44143.0 in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $513370.0 in Q4 2023 to a low of -$50206.0 in Q1 2026.
- Historically, Cash from Financing Activities has averaged $104393.9 across 5 years, with a median of $39118.5 in 2022.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities soared 14571.91% in 2023, then plunged 535.7% in 2025.
- A 5-year view of Cash from Financing Activities shows it stood at $3499.0 in 2022, then jumped by 14571.91% to $513370.0 in 2023, then slumped by 101.35% to -$6944.0 in 2024, then slumped by 535.7% to -$44143.0 in 2025, then fell by 13.73% to -$50206.0 in 2026.
- The last three Cash from Financing Activities figures came in at -$50206.0 (Q1 2026), -$44143.0 (Q4 2025), and $70833.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Veeva Systems | 24.83 Bn | 17.52 Bn | 662.02 Mn | -262.53 Mn |
| 2 | BrightSpring Health Services | 13.57 Bn | 12.69 Bn | 482.22 Mn | -70.02 Mn |
| 3 | Healthequity | 7.20 Bn | 6.93 Bn | 256.31 Mn | -137.18 Mn |
| 4 | Hinge Health | 5.42 Bn | 5.11 Bn | 154.23 Mn | -112.85 Mn |
| 5 | 10x Genomics | 4.46 Bn | 3.92 Bn | 106.18 Mn | -8.42 Mn |
| 6 | Doximity | 3.81 Bn | 3.06 Bn | 125.97 Mn | -93.16 Mn |
| 7 | Waystar Holding | 3.52 Bn | 3.36 Bn | 268.04 Mn | 13.46 Mn |
| 8 | Privia Health | 2.94 Bn | 2.57 Bn | 595.71 Mn | -10.67 Mn |
| 9 | Omnicell | 1.76 Bn | 1.59 Bn | 140.36 Mn | 2.39 Mn |
| 10 | Bioregenx | - | - | 348,288.00 | -50,206.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -50,206.00 |
| Mar 31, 2026 | -50,206.00 |
| Dec 31, 2025 | -44,143.00 |
| Dec 31, 2025 | -44,143.00 |
| Sep 30, 2025 | 70,833.00 |
| Sep 30, 2025 | 70,833.00 |
| Jun 30, 2025 | 16,823.00 |
| Jun 30, 2025 | 16,823.00 |
| Mar 31, 2025 | -10,415.00 |
| Mar 31, 2025 | -10,415.00 |
| Dec 31, 2024 | -6,944.00 |
| Dec 31, 2024 | -6,944.00 |
| Sep 30, 2024 | 46,442.00 |
| Sep 30, 2024 | 46,442.00 |
| Jun 30, 2024 | 120,059.00 |
| Jun 30, 2024 | 120,059.00 |
| Mar 31, 2024 | 282,562.00 |
| Mar 31, 2024 | 282,562.00 |
| Dec 31, 2023 | 513,370.00 |
| Dec 31, 2023 | 513,370.00 |